Titan pharmaceuticals inc (TTNP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
License revenue

-

-

215

15,065

-

-

-

-

-

-

-

Total revenues

3,611

6,618

0

0

-

-

-

-

-

-

-

Operating expenses:
Grant revenue

-

-

0

0

-

-

-

-

-

-

-

License revenue

-

-

-

-

1,671

3,646

9,057

2,325

0

24

79

Royalty revenue

-

-

-

-

-

-

1,424

4,750

3,585

2,512

-

Grant revenue

-

-

-

-

-

-

-

42

483

7,557

-

Total revenues

-

-

215

15,065

1,671

3,646

10,481

7,117

4,068

10,093

79

Cost of goods sold

1,288

538

0

0

-

-

-

-

-

-

-

Research and development

7,242

7,478

9,648

6,126

4,675

4,075

8,309

10,610

11,206

12,855

2,456

Selling, general and administrative

11,925

6,866

5,069

4,596

-

-

-

-

-

-

-

Total operating expenses

20,455

14,882

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

3,755

3,046

3,063

4,877

3,368

3,263

3,438

Total operating expenses

-

-

14,717

10,722

8,430

7,121

11,372

15,487

14,574

16,118

5,894

Loss from operations

-16,844

-8,264

-14,502

4,343

-6,759

-3,475

-891

-8,370

-10,506

-6,025

-5,815

Other expense:
Interest expense, net

-967

-887

-369

37

0

0

-1,568

-4,861

-6,430

-678

-6

Non-cash loss on changes in the fair value of warrants

-1,110

0

-619

-825

4,512

-1,083

-1,737

1,766

-

-

-

Other income (expense), net

17

128

-55

-70

-8

-11

10,433

-183

-

-

-

Non-cash gain on debt extinguishment

226

0

-

-

-

-

-

-

-

-

-

Non-cash gain on changes in the fair value of derivatives

-

-

0

0

-

-

-

-

-

-

-

Other income (expense), net

-

-

-

-

-

-

-

-

129

131

65

Non-cash gain (loss) on changes in the fair value of warrants

-

-

-

-

-

-

-

-

1,862

0

-

Other expense, net

386

-759

195

792

-4,520

1,072

10,602

-6,810

-4,697

-809

-71

Net loss and comprehensive loss

-16,458

-9,023

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-

-

-14,307

5,135

-11,279

-2,403

-

-

-

-6,834

-5,886

Deemed dividend on trigger of down round provision

0

285

0

0

-

-

-

-

-

-

-

Net loss and comprehensive loss attributable to common stockholders

-

-

-14,307

5,135

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-14,307

5,135

-

-

-

-

-

-

-

Gain on retirement of preferred stock upon dissolution of subsidiary

-

-

-

-

-

-

-

-

-

1,241

-

Net loss applicable to common stockholders

-16,458

-9,308

-

-

-

-

9,711

-15,180

-15,203

-5,593

-5,886

Basic net loss per share

-0.72

-1.64

-4.05

1.49

-0.56

-0.14

0.65

-0.23

-0.26

-

-

Diluted net loss per share

-0.72

-1.66

-4.22

1.20

-0.56

-0.20

0.53

-0.23

-0.28

-

-

Weighted average shares used in computing basic net loss per common share

22,957

5,688

3,534

3,457

20,053

17,057

14,927

66,509

59,324

-

-

Weighted average shares used in computing diluted net loss per common share

22,957

5,688

3,538

3,577

20,053

17,060

15,029

66,509

60,392

-

-

Basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-0.09

-0.10

Weighted average shares used in computing basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

59,248

-

Weighted average shares used in computing basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

58,473

License revenue
Total revenues

315

5,376

-

-

-

-

-

-

-

-

-

Product revenue
Total revenues

1,006

535

-

-

-

-

-

-

-

-

-

Grant revenue
Total revenues

2,290

707

-

-

-

-

-

-

-

-

-